Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
Sponsor: ImmuneSensor Therapeutics Inc.
Summary
This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).
Official title: Rollover Study to Continue IMSA101 Treatments in Patients With Advanced Treatment-Refractory Malignancies Previously Enrolled in the Phase I/IIA Safety and Efficacy Study of IMSA101
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
2
Start Date
2023-09-15
Completion Date
2025-09
Last Updated
2024-11-18
Healthy Volunteers
No
Conditions
Interventions
IMSA101
Intra-tumoral administration on Days 1 and 15 of every 28-day cycle
Immune Checkpoint Inhibitor
Administered according to product label
Locations (2)
Honor Health
Scottsdale, Arizona, United States
UC San Diego Moores Cancer Center
La Jolla, California, United States